Expression of microRNA-124 in bladder cancer and its clinical significance

Yang WANG; Yueshi HU; Zheng LI; Qing ZHU; Qixin DUAN; Lei LIU; Huili MA; Minglin LI

doi:10.16016/j.1000-5404.201912083

您当前的位置：

首页 >

文章列表页 >

Expression of microRNA-124 in bladder cancer and its clinical significance

Clinical Medicine | 更新时间：2026-01-09

- Expression of microRNA-124 in bladder cancer and its clinical significance
- Journal of Third Military Medical University Vol. 42, Issue 10, Pages: 1035-1041(2020)
- 作者机构：
  
  1.473009 河南南阳，河南省南阳市中心医院：泌尿外科
  2.473009 河南南阳，河南省南阳市中心医院：肿瘤内科
- 作者简介：
- 基金信息：
- DOI：10.16016/j.1000-5404.201912083
  CLC： R394.3;R730.23;R737.14
- Received：10 December 2019，
  
  Revised：2020-03-13，
  
  Published：30 May 2020
- 稿件说明：
移动端阅览
Yang WANG, Yueshi HU, Zheng LI, et al. Expression of microRNA-124 in bladder cancer and its clinical significance[J]. Journal of Third Military Medical University, 2020, 42(10): 1035-1041.
DOI：

Yang WANG, Yueshi HU, Zheng LI, et al. Expression of microRNA-124 in bladder cancer and its clinical significance[J]. Journal of Third Military Medical University, 2020, 42(10): 1035-1041. DOI： 10.16016/j.1000-5404.201912083.

摘要

目的

探讨miR-124在膀胱癌中的表达及其临床意义。

方法

RT-qPCR检测人正常膀胱尿路上皮细胞SV-HUC-1及膀胱癌细胞(5637、J82、T24、TCCSUP、UM-UC-3)中miR-124的表达；收集本院2013年1月至2016年1月114例膀胱癌患者的术后组织标本，采用原位杂交法检测miR-124在膀胱癌及癌旁组织中的表达，并分析其与临床病理特征及预后的相关性。细胞试验分3组：分别将miRNA-NC(miRNA-NC组)、miRNA-124 mimics(miRNA-124 mimics组)和miR-124 inhibitor(miR-124 inhibitor组)转染至膀胱癌T24细胞，CCK-8试验检测miR-124表达对细胞增殖能力的影响，Western blot检测其增殖相关蛋白(PCNA、Ki-67)和p-AKT表达。

结果

qPCR结果显示，miR-124在膀胱癌细胞5637、J82、T24、TCCSUP、UM-UC-3中的表达均低于正常膀胱尿路上皮细胞SV-HUC-1(

0.05)；原位杂交试验结果显示，miR-124在正常膀胱尿路上皮细胞中呈高表达，在非浸润性和浸润性膀胱癌组织中低表达；miR-124表达与膀胱癌临床T分期、淋巴结转移及肿瘤分化程度密切相关(

=6.829，

=0.009；

=6.844，

=0.009；

=5.111，

=0.024)；Kaplan-Meier分析显示，miR-124低表达组患者的总生存率(OS)和无病生存期(DFS)明显低于高表达组患者(

=22.7

0.01；

=26.57

0.01)。多因素分析结果表明miR-124低表达是影响膀胱癌患者预后的独立危险因素(OS HR=4.63; 95%

:1.39~7.23;

=0.007; DFS HR=5.82; 95%

: 1.56~11.42;

=0.003)。与miRNA-NC组比较，miR-124mimics组T24细胞增殖能力明显下降(

0.05)，增殖相关蛋白(PCNA、Ki-67)和p-AKT表达量明显降低(

0.05)；而miR-124 inhibitor组中T24细胞增殖能力增强，PCNA、Ki-67及p-AKT的蛋白表达量升高(

0.05)。

结论

miR-124在膀胱癌细胞及组织中低表达，并促进膀胱癌细胞的增殖能力，低表达miR-124的膀胱癌患者预后较差，其机制可能与AKT信号通路的激活有关。

Abstract

Objective

To investigate the expression of microRNA-124 (miR-124) in bladder cancer and its clinical significance.

Methods

The expression of miR-124 in a normal bladder urothelial cell line (SV-HUC-1) and 5 bladder cancer cell lines (5 637

J82

T24

TCCSUP and UM-UC-3) was detected using RT-qPCR. We also detected the expression of miR-124 using

in situ

hybridization in 114 tissue specimens of bladder cancer and adenocarcinoma tissues from patients undergoing surgeries in our hospital between January

2013 and January

2016. The correlations of miR-124 expression with the clinicopathological characteristics and prognosis of the patients were analyzed. In the

in vitro

experiment

we tested the effect of transfection with miR-124 mimics and miR-124 inhibitor on the proliferation of bladder cancer T24 cells using CCK-8 assay and on the cellular expression of PCNA

Ki-67 and p-AKT using Western blotting.

Results

The expression of miR-124 in the 5 bladder cancer cell lines was significantly lower than that in normal bladder urothelial cells. The results of

in situ

hybridization showed that miR-124 was highly expressed in normal bladder urothelial cells but lowly expressed in non-invasive and invasive bladder cancer tissues. The expression of miR-124 was closely correlated with clinical T stage (

Chi

-square=6.829

=0.009)

lymph node metastasis (

Chi

-square= 6.844

=0.009) and tumor differentiation (

Chi

-square=5.111

=0.024). Kaplan-Meier analysis showed that compared with those with a high expression of miR-124

the patients with a low expression of miR-124 had significantly shorter overall survival (

Chi

-square=22.7

0.01) and disease-free survival (

Chi

-square=26.57

0.01). Multivariate analysis showed that a low expression of miR-124 was an independent risk factor for a poor prognosis in patients with bladder cancer in terms of both th

e overall survival (HR=4.63

95%

: 1.39~7.23;

=0.007) and disease-free survival (HR=5.82

95%

: 1.56~11.42;

=0.003). In the cell experiment

transfection with the miR-124 mimics significantly attenuated the proliferation of T24 cells (

0.05) and lowered the expressions of proliferation-related proteins (PCNA

Ki-67) and p-AKT as compared with the negative control (

0.05)

while transfection with the miR-124 inhibitor resulted in the reverse changes (

0.05).

Conclusion

The low expression of miR-124 in bladder cancer cells and tissues can promote cancer cell proliferation and is associated with a poor prognosis of the patients possibly in relation with the activation of AKT signaling pathway.

关键词

Keywords

references

CUI J, ZHOU B, ROSS S A, et al . Nutrition, microRNAs, and human health[J ] . Adv Nutr, 2017, 8(1): 105-112. DOI: 10.3945/an.116.013839.

ZENDJABIL M, FAVARD S, TSE C, et al . The microRNAs as biomarkers: What prospects?[J ] . C R Biol, 2017, 340(2): 114-131. DOI: 10.1016/j.crvi.2016.12.001.

SHI P, CHEN C, LI X, et al . MicroRNA-124 suppresses cell proliferation and invasion of triple negative breast cancer cells by targeting STAT3[J ] . Mol Med Rep, 2019, 19(5): 3667-3675. DOI: 10.3892/mmr.2019.10044.

JIA X, WANG X, GUO X, et al . MicroRNA-124: An emerging therapeutic target in cancer[J ] . Cancer Med, 2019, 8(12): 5638-5650. DOI: 10.1002/cam4.2489.

THOMA C. Combining epigenetic and immune checkpoint inhibitors in bladder cancer[J]. NatRev Urol, 2019, 16(9): 507. DOI: 10.1038/s41585-019-0221-3.

SIEGEL R L, MILLER K D, JEMAL A. Cancer statistics, 2019[J]. CA Cancer J Clin, 2019, 69(1): 7-34. DOI: 10.3322/caac.21551.

DESANTIS C E, MILLER K D, DALE W, et al . Cancer statistics for adults aged 85 years and older, 2019[J ] . CA Cancer J Clin, 2019, 69(6): 452-467. DOI: 10.3322/caac.21577.

ELSHARKAWI F, ELSABAH M, SHABAYEK M, et al . Urine and serum exosomes as novel biomarkers in detection of bladd er cancer[J ] . Asian Pac J Cancer Prev, 2019, 20(7): 2219-2224. DOI: 10.31557/APJCP.2019.20.7.2219.

LI Q, WANG H, PENG H, et al . MicroRNAs: Key Players in Bladder Cancer[J ] . Mol Diagn Ther, 2019, 23(5): 579-601. DOI: 10.1007/s40291-019-00410-4.

ORSO F, QUIRICO L, DETTORI D, et al . Role of miRNAs in tumor and endothelial cell interactions during tumor progression[J ] . Semin Cancer Biol, 2019, pii: S1044-579X(19)30169-5. DOI: 10.1016/j.semcancer.2019.07.024.

VOS P D, LEEDMAN P J, FILIPOVSKA A, et al . Modulation of miRNA function by natural and synthetic RNA-binding proteins in cancer[J ] . Cell Mol Life Sci, 2019, 76(19): 3745-3752. DOI: 10.1007/s00018-019-03163-9.

ZHANG Y, ROTH JA, YU H, et al . A 5-MicroRNA signature identified from serum MicroRNA profiling predicts survival in patients with advanced stage non-small cell lung cancer[J ] . Carcinogenesis, 2019, 40(5): 643-650. DOI: 10.1093/carcin/bgy132.

REN C, CHEN H, HAN C, et al . High expression of miR-16 and miR-451 predicating better prognosis in patients with gastric cancer[J ] . J Cancer Res Clin Oncol, 2016, 142(12): 2489-2496. DOI: 10.1007/s00432-016-2243-z.

ZHU C, REN C, HAN J, et al . A five-microRNA panel in plasma was identified as potential biomarker for early detection of gastric cancer[J ] . Br J Cancer, 2014, 110(9): 2291-2299. DOI: 10.1038/bjc.2014.119.

MA J, WENG L, WANG Z, et al . MiR-124 induces autophagy-related cell death in cholangiocarcinoma cells through direct targeting of the EZH2-STAT3 signaling axis[J ] . Exp Cell Res, 2018, 366(2): 103-113. DOI: 10.1016/j.yexcr.2018.02.037.

YU F, LIU J B, WU Z J, et al . Tumor suppressive microRNA-124a inhibits stemness and enhances gefitinib sensitivity of non-small cell lung cancer cells by targeting ubiquitin-specific protease 14[J ] . Cancer Lett, 2018, 427: 74-84. DOI: 10.1016/j.canlet.2018.04.022.

LI X, YU Z, LI Y, et al . The tumor suppressor miR-124 inhibits cell proliferation by targeting STAT3 and functions as a prognostic marker for postoperative NSCLC patients[J ] . Int J Oncol. 2015, 46(2): 798-808. DOI: 10.3892/ijo.2014.2786.

LU M L, ZHANG Y, LI J, et al . MicroRNA-124 inhibits colorectal cancer cell proliferation and suppresses tumor growth by interacting with PLCB1 and regulating Wnt/β-catenin signaling pathway[J ] . Eur Rev Med Pharmacol Sci, 2019, 23(1): 121-136. DOI: 10.26355/eurrev_201901_16756.

CAO Z, XU L, ZHAO S, et al . The functions of microRNA-124 on bladder cancer[J ] . Onco Targets Ther, 2019, 12: 3429-3439. DOI: 10.2147/OTT.S193661.

LIM H J, CROWE P, YANG J L. Current clinical regulation of PI3K/PTEN/Akt/mTOR signalling in treatment of human cancer[J]. J Cancer Res Clin Oncol, 2015, 141(4): 671-689. DOI: 10.1007/s00432-014-1803-3.

HOUÉDÉ N, POURQUIER P. Targeting the genetic alterations of the PI3K-AKT-mTOR pathway: its potential use in the treatment of bladder cancers[J]. Pharmacol Ther, 2015, 145: 1-18. DOI: 10.1016/j.pharmthera.2014.06.004.

Views

下载量

CSCD

Alert me when the article has been cited

提交

Tools

Publicity Resources

Starvation microenvironment activates Yes-associated protein 1 to regulate autophagy and promote proliferation of bladder cancer cells

Promoting effect of ultra-low dose DMSO on fibroblast proliferation and its underlying mechanism

GPX7 regulates proliferation and senescence of hepatocellular carcinoma cells through the PI3K-AKT pathway

Mechanism of abnormal specification of spermatogonial stem cells after Rb1 knockout in mitotic-arrested prospermatogonia

Related Author

李庭浩

童行

曹洪豪

刘旭东

朱俊龙

秦子家

尹思文

何卫阳

Related Institution

Center for Dermatology and Medical Cosmetology， the Second Affiliated Hospital of Chongqing Medical University

Department of Dermatology， Plastic and Cosmetic Surgery， Wushan People’s Hospital

Faculty of Hepatobiliary and Pancreatic Surgery， First Medical Center， General Hospital of PLA， Beijing, Air Force Medical Center of PLA

Department of Hepatobiliary Surgery， Eighth Medical Center， General Hospital of PLA， Beijing, Air Force Medical Center of PLA

Department of Radiation Oncology, Air Force Medical Center of PLA

⁰